Table 1 HSP27 and 70 expression in TETs and analysis of clinicopathologic characteristics.

From: HSP27 and 70 expression in thymic epithelial tumors and benign thymic alterations: diagnostic, prognostic and physiologic implications

Clinicopathologic characteristics

 

HSP expression in TETs

Cyto HSP27

Cyto HSP70

Nucl HSP70

n

mean ± SEM

n

mean ± SEM

n

mean ± SEM

WHO

A

16

2.63 ± 0.1

16

2.0 ± 0.2

16

2.44 ± 0.2

AB

14

2.54 ± 0.1

14

2.5 ± 0.2

14

2.61 ± 0.2

B1

10

2.30 ± 0.2

11

1.55 ± 0.4

11

1.86 ± 0.3

B2

21

2.79 ± 0.1

21

2.29 ± 0.2

21

2.60 ± 0.2

B3

17

2.85 ± 0.1

17

2.0 ± 0.1

17

2.38 ± 0.2

TC

15

2.93 ± 0.1

15

2.1 ± 0.2

15

2.23 ± 0.3

MNT

4

3.0 ± 0.0

4

2.5 ± 0.3

4

2.5 ± 0.3

TNET

3

0.5 ± 0.3

3

1.33 ± 0.4

3

0.33 ± 0.3

p-value

  

 < 0.001 a

 

0.061 a

 

0.003 a

Masaoka-Koga Stage

I

23

2.52 ± 0.1

23

2.30 ± 0.1

23

2.59 ± 0.1

II

46

2.64 ± 0.1

47

2.17 ± 0.1

47

2.39 ± 0.1

III

15

2.67 ± 0.2

15

1.97 ± 0.2

15

2.37 ± 0.3

IV

16

2.63 ± 0.2

16

1.78 ± 0.3

16

1.75 ± 0.3

p-value

  

0.770 a

 

0.261 a

 

0.037 a

  1. HSP27 and 70 were strongly expressed in all thymomas and TCs but weak or absent in TNETs. Strongest nuclear HSP70 expression was found in non-invasive TETs (Masaoka-Koga stage I), whereas the weakest expression was found in metastatic TETs (Masaoka-Koga stage IV). Paraneoplastic MG had no significant difference on HSP27 and 70 staining intensities in TETs. HSP27 , Heat Shock Protein 27; HSP70 , Heat Shock Protein 70; n , number; Cyto , cytoplasmic expression; Nucl ., nuclear expression; WHO , World Health Organization; TC , Thymic Carcinoma; MNT , Micronodular Thymoma; TNET , Thymic Neuroendocrine Tumor; MG , Myasthenia Gravis; SEM , standard error of the mean.
  2. aOne-way Anova.
Back to article page